add B7

CLAIMS

1. Use of a mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional, in the manufacture of a medicament for use in treating a non-neuronal cancer.

2. Use according to claim 1, wherein the medicament is for use in treating a human with a non-neuronal cancer.

3. Use according to claim 1 ~~or 2~~, wherein the cancer is a primary tumor.

4. Use according to claim 1 ~~or 2~~, wherein the cancer is a metastatic tumor.

5. Use according to claim 1 ~~or 2~~, wherein the cancer is a mesothelioma, ovarian carcinoma, bladder cancer or melanoma.

6. Use according to ~~any one of the preceding claims,~~ Claim 1 wherein the mutant herpes simplex virus is a type 1 herpes simplex virus.

7. Use according to ~~any one of the preceding claims,~~ Claim 1 wherein the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.

8. Use according to claim 7, wherein the modification is a deletion of from 0.1 to 3kb.

9. Use according to claim 8, wherein the deletion is from 0.7 to 0.8kb.

10. Use according to ~~any one of the preceding claims,~~ Claim 1 wherein the mutant herpes simplex virus is strain 1716.

11. A method of treating a non-neuronal cancer in a mammal, which method comprises the step of administering to the mammal an effective amount of a mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional.

12. An agent for treating a non-neuronal cancer,

comprising a mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional.

add D1 add F1